67/100BMerck & Co company profile
- CEO
- Robert Davis
- Employees
- 74,000
- Headquarters
- 126 East Lincoln Avenue, Rahway, NJ 07065, US
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO date
- 13 Jan 1978
- Stock exchange
- NYSE
- ISIN
- US58933Y1055
Website:merck.com
About the company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Employees
Merck & Co had about 75,000 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 0.0% more than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Merck & Co
Institutions such as funds, banks and insurers held 82.3% of Merck & Co's shares on 30 June 2026, 3,954 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Merck & Co
Source: Financial Modeling Prep